Gilead Must Pay Merck $200 Million for Hepatitis C PatentsBy and
Merck demanded royalty saying it paved way for liver remedy
Gilead failed to convince jury Merck drug patents are invalid
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
You might like: